Drug class in one race
IL-23 p19 drugs for Psoriasis
7 tracked IL-23 p19 drugs in the Psoriasis race. The class explanation lives on the IL-23 p19 page; the full indication pipeline across every mechanism is on the Psoriasis page.
3 approved / phase 42 Phase 32 Phase 2
Head-to-head evidence: HS-20137 vs SHR-1139 · guselkumab vs HS-20137 · HS-20137 vs picankibart · HS-20137 vs risankizumab · HS-20137 vs tildrakizumab · ORKA-001 vs SHR-1139